Targeting BCL-2 regulated apoptosis in cancer.
Kirsteen J CampbellStephen W G TaitPublished in: Open biology (2019)
The ability of a cell to undergo mitochondrial apoptosis is governed by pro- and anti-apoptotic members of the BCL-2 protein family. The equilibrium of pro- versus anti-apoptotic BCL-2 proteins ensures appropriate regulation of programmed cell death during development and maintains organismal health. When unbalanced, the BCL-2 family can act as a barrier to apoptosis and facilitate tumour development and resistance to cancer therapy. Here we discuss the BCL-2 family, their deregulation in cancer and recent pharmaceutical developments to target specific members of this family as cancer therapy.
Keyphrases
- cancer therapy
- cell death
- oxidative stress
- cell cycle arrest
- endoplasmic reticulum stress
- papillary thyroid
- drug delivery
- anti inflammatory
- healthcare
- squamous cell
- mental health
- molecular dynamics
- stem cells
- single cell
- cell therapy
- lymph node metastasis
- cell proliferation
- molecular dynamics simulations
- amino acid
- childhood cancer
- climate change